Genetically modified mesenchymal stem cell therapy for acute respiratory distress syndrome

Table 2 Research regarding application of gene modified MSCs in preclinical ARDS models

Candidate gene	Engineering vector	Animal species	ARDS model	MSC source	MSC species	MSC dose	Administration route	References
CXCR4	Lentiviral vector	Rat	LPS-induced	Bone marrow	Rat	1 × 10⁶	Tail vein	[53]
EP2	Lentiviral vector	Mice	LPS-induced	Bone marrow	Mice	5 × 10⁵	Tail vein	[54]
sST2	Lentiviral vector	Mice	LPS-induced	Adipose tissue	Human	1 × 10⁶	Tail vein	[60]
ACE2	Lentiviral vector	Mice	LPS-induced	Bone marrow	Mice	5 × 10⁵	Tail vein	[63]
KGF	Lentiviral vector	Mice	LPS-induced	Bone marrow	Mice	5 × 10⁵	Tail vein	[67]
HGF	Adenoviral vector	Mice	radiation-induced	Bone marrow	Human	1 × 10⁶	Tail vein	[72]
Ang-1	Lentiviral vector	Mice	LPS-induced	Bone marrow	Mice	1 × 10⁵	Jugular vein	[79]
Ang-1	Nuclear-targeting electroporation	Mice	LPS-induced	Bone marrow	Mice	2.5 × 10⁵	Jugular vein	[80]
MnSOD	Lentiviral vector	Mice	radiation-induced	Bone marrow	Human	1 × 10⁶	Tail vein	[85]
HO-1	Lentiviral vector	Rat	LPS-induced	Bone marrow	Rat	5 × 10⁵	Tail vein	[86]

ARDS acute respiratory distress syndrome, CXCR4 chemokine receptor 4, LPS lipopolysaccharide, EP2 E-prostanoid 2, sST2 soluble IL-1 receptor-like-1, ACE2 angiotensin-converting enzyme 2, KGF keratinocyte growth factor; HGF, hepatocyte growth factor, Ang-1 angiopoietin-1, HO-1 heme oxygenase-1, MnSOD manganese superoxide dismutase

ISSN: 1757-6512